Amryt Pharma (#AMYT) confirms launch of phase 3 clinical trial of AP101
- 2017-03-27 23:16:34
UK 16:18 Monday, 26 October 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
Shore cap is House broker to Amryt Pharma (AMYT) so everything it writes cannot be said to be any way shape or form impartial. And since we own a shed load of the shares we are biased as hell too. Having said that this note is detailed and lifting the target price from 35p to 88p in light of recent news is pretty dramatic given that the shares were 18.5p on Friday when this "most excellent" research note came out.
Amryt (AMYT) has announced that it has completed of discussions with the Food and Drug Administration, the US FDA, and European Medicines Agency regarding the design of its pivotal phase 3 clinical trial for AP101 as a potential treatment for Epidermolysis Bullosa. The global market for a treatment for EB is, according to Amryt, worth £1.3 billion.
No news for six weeks and then two pieces of good news in two days, such is the way of life for we shareholders in Amryt (AMYT). Let us start with the rats.
Boy did Amryt bore its loyal shareholders, including us, to tears for most of 2016. Owning this stock, formerly a failed oil explorer Fastnet, was like watching paint dry. Amid a totally understandable ennui the shares drifted back to lows of just under 14p which - as we had tipped the shares at 18.4p and bought ourselves at higher levels - was a bit of a pain. But then in November it roared into life and the shares are now 18.5p-20.5p and are my second buy tip of the year at up to 22p.
We tipped Amryt Pharma (AMYT) pre-consolidation at an effective 18.4p earlier this year and until last week it all went quiet. Now it has roared into life and the shares are 18.5p-20.5p. So what happened? And what next?
I am a loyal shareholder and think that shares in Amryt (AMYT) are cheap and a deal today really does look like very good news indeed. But the buy note from broker Stifel has me a bit confused. Let me explain.
Amryt Pharma (AMYT) has announced that it has secured a €20m debt facility from the European Investment Bank on, what broker Stifel says, are very attractive commercial terms. Stifel says that the facility will not only extend the company's funding until well into 2019, but also provide funding for development of acromegaly product AP102 and potential launch funding for Episalvan in partial thickness wounds. Stifel concludes that the shares are a buy at 14p with a price target of 49p. Yes indeed. Since we own the shares I thought we'd share the note with you.
Cathal Friel did the right thing in turning Fastnet (an oil company) into Amryt (AMYT) a pharmaceuticals play. We bought into the RTO placing. Here is Cathal explaining the story at UK Investor Show. Enjoy
As usual I had a great day at the UK Investor Show, especially listening to many of the informative speakers on the main stage.
